Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297085440> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- W4297085440 endingPage "18" @default.
- W4297085440 startingPage "16" @default.
- W4297085440 abstract "Cefotaxime plus minocycline has been shown to have synergistic activity against Vibrio vulnificus; however, the clinical role of cefazolin in combination with minocycline in immunocompromised hosts has not been established. Therefore, antimicrobial susceptibility of the V. vulnificas clinical isolate Vv05191 was studied by the agar dilution method. Antibacterial activity of cefazolin, minocycline, and a combination of the two drugs was investigated by time-kill studies in vitro and further examined for therapeutic efficacy in a murine model. When cefazolin at a combination of 4 mg/L (1/2 × MIC) was combined with minocycline at a concentration of 0.03 mg/L (1/2 × MIC), sustained inhibitory activity was noted until 24 h. In BALB/cByJ mice with cyclophosphamide-induced neutropenia, an inoculum of 1.5 × 108 CFU caused death within 96 h when the infected mice were treated by cefazolin (400 mg/kg every 3 h), while 6.3% of mice survived when treated by minocycline (4 mg/kg stat, then 2 mg/kg every 12 h). However, 62.5% of mice survived for 96 h when mice were treated by cefazolin (400 mg/kg every 3 h) plus minocycline (4 mg/kg stat, then 2 mg/kg every 12 h) (P = 0.002, log rank test). In conclusion, cefazolin in combination with minocycline exhibits in vitro synergistic antibacterial activity against V. vulnificus and provides a therapeutic advantage in neutropenic mice with V. vulnificus infection." @default.
- W4297085440 created "2022-09-27" @default.
- W4297085440 creator A5008314407 @default.
- W4297085440 creator A5033057741 @default.
- W4297085440 creator A5035955045 @default.
- W4297085440 creator A5055024129 @default.
- W4297085440 creator A5078428149 @default.
- W4297085440 date "2010-01-29" @default.
- W4297085440 modified "2023-10-18" @default.
- W4297085440 title "Cefazolin Plus Minocycline against a Clinical Isolate of <i>Vibrio vulnificus</i>: In Vitro and Animal Studies" @default.
- W4297085440 doi "https://doi.org/10.7883/yoken.63.16" @default.
- W4297085440 hasPublicationYear "2010" @default.
- W4297085440 type Work @default.
- W4297085440 citedByCount "4" @default.
- W4297085440 countsByYear W42970854402016 @default.
- W4297085440 countsByYear W42970854402017 @default.
- W4297085440 countsByYear W42970854402019 @default.
- W4297085440 countsByYear W42970854402020 @default.
- W4297085440 crossrefType "journal-article" @default.
- W4297085440 hasAuthorship W4297085440A5008314407 @default.
- W4297085440 hasAuthorship W4297085440A5033057741 @default.
- W4297085440 hasAuthorship W4297085440A5035955045 @default.
- W4297085440 hasAuthorship W4297085440A5055024129 @default.
- W4297085440 hasAuthorship W4297085440A5078428149 @default.
- W4297085440 hasBestOaLocation W42970854401 @default.
- W4297085440 hasConcept C176947019 @default.
- W4297085440 hasConcept C185592680 @default.
- W4297085440 hasConcept C202751555 @default.
- W4297085440 hasConcept C2776520383 @default.
- W4297085440 hasConcept C2778275353 @default.
- W4297085440 hasConcept C2778353156 @default.
- W4297085440 hasConcept C2778458500 @default.
- W4297085440 hasConcept C2780493024 @default.
- W4297085440 hasConcept C4937899 @default.
- W4297085440 hasConcept C501593827 @default.
- W4297085440 hasConcept C523546767 @default.
- W4297085440 hasConcept C54355233 @default.
- W4297085440 hasConcept C55493867 @default.
- W4297085440 hasConcept C71924100 @default.
- W4297085440 hasConcept C86803240 @default.
- W4297085440 hasConcept C89423630 @default.
- W4297085440 hasConcept C98274493 @default.
- W4297085440 hasConceptScore W4297085440C176947019 @default.
- W4297085440 hasConceptScore W4297085440C185592680 @default.
- W4297085440 hasConceptScore W4297085440C202751555 @default.
- W4297085440 hasConceptScore W4297085440C2776520383 @default.
- W4297085440 hasConceptScore W4297085440C2778275353 @default.
- W4297085440 hasConceptScore W4297085440C2778353156 @default.
- W4297085440 hasConceptScore W4297085440C2778458500 @default.
- W4297085440 hasConceptScore W4297085440C2780493024 @default.
- W4297085440 hasConceptScore W4297085440C4937899 @default.
- W4297085440 hasConceptScore W4297085440C501593827 @default.
- W4297085440 hasConceptScore W4297085440C523546767 @default.
- W4297085440 hasConceptScore W4297085440C54355233 @default.
- W4297085440 hasConceptScore W4297085440C55493867 @default.
- W4297085440 hasConceptScore W4297085440C71924100 @default.
- W4297085440 hasConceptScore W4297085440C86803240 @default.
- W4297085440 hasConceptScore W4297085440C89423630 @default.
- W4297085440 hasConceptScore W4297085440C98274493 @default.
- W4297085440 hasIssue "1" @default.
- W4297085440 hasLocation W42970854401 @default.
- W4297085440 hasOpenAccess W4297085440 @default.
- W4297085440 hasPrimaryLocation W42970854401 @default.
- W4297085440 hasRelatedWork W101175796 @default.
- W4297085440 hasRelatedWork W2000254418 @default.
- W4297085440 hasRelatedWork W2003236893 @default.
- W4297085440 hasRelatedWork W2183104323 @default.
- W4297085440 hasRelatedWork W2207033334 @default.
- W4297085440 hasRelatedWork W2364319055 @default.
- W4297085440 hasRelatedWork W2403412381 @default.
- W4297085440 hasRelatedWork W2417261932 @default.
- W4297085440 hasRelatedWork W3207449696 @default.
- W4297085440 hasRelatedWork W4296259988 @default.
- W4297085440 hasVolume "63" @default.
- W4297085440 isParatext "false" @default.
- W4297085440 isRetracted "false" @default.
- W4297085440 workType "article" @default.